Different Therapeutic Strategies in 2 Young Patients with Advanced ALK-Rearranged Lung Adenocarcinoma: “The Light at the End of the Tunnel”

Malignant pleural effusion represents a prognostic negative factor on survival conferring stage IV disease. The median of survival is 5 months and a 5-year survival of about 3%. We describe the therapeutic success obtained from different strategies in anaplastic lymphoma kinase (ALK) inhibitors in 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Caterino, Umberto, Cesaro, Cristiano, Zamparelli, Enzo, Cesaro, Flavio, Palma, Alba, Lucci, Raffaella, Imitazione, Pasquale, Casazza, Dino, Amore, Dario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8647055/
https://www.ncbi.nlm.nih.gov/pubmed/34950005
http://dx.doi.org/10.1159/000520127

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8647055/
https://www.ncbi.nlm.nih.gov/pubmed/34950005
http://dx.doi.org/10.1159/000520127

Ejemplares similares